Martin Shkreli Ousted As CEO From Another Drug Company

This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated.

Drugmaker KaloBios Pharmaceuticals (KBIO) on Monday said it terminated Martin Shkreli as CEO the same day last week the hedge fund investor and pharmaceutical industry executive was arrested on securities fraud charges.

While making the announcement in a statement, the company did not say whether it was looking for an interim CEO or permanent CEO to replace Shkreli. KaloBios did not return calls requesting comment.

Shkreli resigned from the company’s board of directors and from its audit committee, KaloBios said in a statement. “There were no disagreements with the company that led to the resignations,” the company said in a regulatory filing.

Shkreli last month purchased a majority stake in KaloBios and named himself chief executive officer. Three individuals were named to the company’s board of directors, replacing its prior members, who resigned. Tony Chase, one of the individuals who joined the board when Shkreli took the helm, has resigned, the company said on Monday in its press release. No mention was made of either David Moradi or Marek Biestek, both of whom were also elected to the board of KaloBios when Shkreli took over the company.

Moradi, who runs a New York-based hedge fund Anthion Management, did not return calls for comment.

When CBS MoneyWatch called a New York number listed as a contact for Shkreli on a news release announcing his November 19 appointment as CEO of KalosBios, we were directed to Ed Painter, head of communications and investor relations at Turing Pharmaceuticals, the company from which Shkreli resigned from on Friday. Painter declined to confirm or deny any relationship with KalosBios.

Trading of KaloBios shares were halted on Thursday, after the 32-year-old Shkreli was arrested for allegedly running a Ponzi-like scheme at a hedge fund he formerly ran and then at Turing. Trading will not resume until the company satisfied Nasdaq’s request for additional information, the exchange said in a statement. Nasdaq spokesman Will Briganti said he could not offer further comment.

As CEO of Turing, Shkreli drew public ire after he raised the price of a life-saving drug to $750 from $13.50.